Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a single-stranded RNA virus, which belongs to the beta coronavirus family. SARS-CoV-2 infection associates with a broad range of symptoms that starts asymptomatically and then leads to a mild and noninflammatory syndrome. Kidney involvement in COVID-19 disease depends on several factors like direct cytopathic effects of infection through an ACE2 (angiotensin-converting enzyme-2)-dependent pathway, hemodynamic changes, and increased coagulation. Consistent control of serum and urinary creatinine and hemodynamic conditions in patients with kidney disorders results in decreased occurrence of acute kidney injury (AKI) by COVID-19 or reduce its intensity. Improvement of oxygen saturation, using vasoactive peptide to increase kidney perfusion, and active antiviral treatment are some clinical interventions to alleviate disorders in kidney function. Based on the abovementioned considerations, prevention is the most effective way of dealing with COVID-19.